[{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Merdury Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Ainos"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Taiwan Tanabe Seiyaku","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Taiwan Tanabe Seiyaku","highestDevelopmentStatusID":"12","companyTruncated":"Ainos \/ Taiwan Tanabe Seiyaku"}]

Find Clinical Drug Pipeline Developments & Deals by Ainos

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The partnership between Ainos and Taiwan Tanabe Seiyaku aims to accelerate the global market launch of Veldona (Interferon Alfa) for the treatment of Sjögren's syndrome.

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Undisclosed

December 02, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Immunology

Highest Development Status : Approved

Sponsor : Taiwan Tanabe Seiyaku

Deal Size : Undisclosed

Deal Type : Partnership

blank

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for patients with Sjögren's syndrome.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

November 11, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Immunology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

September 17, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Undisclosed

May 07, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Hematology

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : $9.0 million

Deal Type : Financing

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

February 05, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Undisclosed

January 24, 2024

Lead Product(s) : Interferon Alfa

Therapeutic Area : Hematology

Highest Development Status : IND Enabling

Sponsor : Lind Partners

Deal Size : $1.7 million

Deal Type : Financing

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

November 21, 2023

Lead Product(s) : Interferon Alfa

Therapeutic Area : Oncology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug c...

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

September 18, 2023

Lead Product(s) : Interferon Alfa

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Undisclosed

March 14, 2023

Lead Product(s) : Interferon Alfa

Therapeutic Area : Oncology

Highest Development Status : Phase II

Recipient : Merdury Pharmaceutical

Deal Size : Undisclosed

Deal Type : Agreement

blank

10

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce i...

Product Name : Veldona

Product Type : Large molecule

Upfront Cash : Not Applicable

October 31, 2022

Lead Product(s) : Interferon Alfa

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank